Published in Health and Medicine Week, December 8th, 2003
According to a study from the United States, "We have recently recognized humoral rejection in lung allograft recipients and its association with acute and chronic graft dysfunction.
"We have shown that C4d, a stable marker of classic complement activation, is deposited in lung allografts, correlating with clinical rejection and parenchymal injury," wrote C.M. Magro and colleagues, Ohio State University, Department of Pathology.
"The antigenic target may be endothelium in the setting of recurrent acute rejection while varying components of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.